Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation Board names Dr. Daniel Jorgensen as Chief Executive Officer TUCSON, Ariz., Sept. 27, 2022 — Critical Path Institute (C-Path) tod
C-Path’s European Nonprofit Appoints Managing Director and New Board Member to Expand Global Efforts TUCSON, Ariz. and AMSTERDAM, September 20, 2022 — Critical Path Institute’s (C-Path) European nonprofit today announced the ap
Rare Disease Workshop Highlights the Importance of Data Sharing in Drug Development C-Path, NORD and FDA hosted an annual workshop September 13-14 to spotlight the impact of their innovative data and analytics plat
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases TUCSON, Ariz., Sept. 14, 2022 — Critical Path Institute (C-Path) has announced it will serve as the convener of the Critical Pat
C-Path’s Kristen Swingle Named President Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-
C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases TUCSON, Ariz., Sept. 1, 2022 — Critical Path Institute (C-Path) today announced the launch of a pre-consortium collaboration foc
Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug Development C-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platfo
Oak Hill Bio Joins C-Path’s International Neonatal Consortium TUCSON, Ariz., Aug. 24, 2022 — Critical Path Institute (C-Path) today announced that Oak Hill Bio (Oak Hill), a clinical-stage n
C-Path’s Dr. Amanda Klein Promoted to Transplant Therapeutic Consortium Executive Director TUCSON, Ariz., July 14, 2022 — Critical Path Institute (C-Path) has named Amanda Klein, Pharm.D., as Executive Director for its
Diamyd Medical Joins International Consortium in Type 1 Diabetes TUCSON, Ariz., June 30, 2022 — Diamyd Medical will be a full voting member of the Type 1 Diabetes Consortium (T1DC) led by the U
